



**LIST OF ART CITED BY APPLICANT**

ATTY. DOCKET: 17595 (BOT)	SERIAL NO.: 10/621,054
APPLICANT: JAN K. CAERS et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE: JULY 15, 2003	GROUP: 1645

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CWA	AA	3,547,121	12-15-1970	CHERRY	128	215	
CWA	AB	4,642,096	02-10-1987	KATZ	604	116	
CWA	AC	6,036,632	03-14-2000	WHITMORE, III et al.	600	7	
	AD						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
CWA	BA	EP 0914819 A1	11-07-1997	Europe	A61K	9/70	Y
CWA	BB	GB 2 202 445 A	02-25-1987	UK	A61M	5/00	Y
CWA	BC	WO 02/068028 A1	02-27-2001	PCT	A61M	5/42	Y
	BD						

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	
	CB	
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	
	CI	
	CJ	
	CK	
	CL	
	CM	
	CN	
	CO	

EXAMINER [Signature] DATE CONSIDERED 3/2/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17595 (BOT)	SERIAL NO.: 10/621,054
APPLICANT CAERS, J. et al	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE: July 15, 2003	GROUP 1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
CMA	AA	5,437,291	8-1-1995	Pasricha et al.			
	AB	5,670,484	9-23-1997	Binder			
	AC	5,714,468	2-3-1998	Binder			
	AD	5,766,605	6-16-1998	Sanders et al.			
	AE	6,063,768	5-16-2000	First			
	AF	6,113,915	9-5-2000	Aoki et al.			
	AG	6,139,845	10-31-2000	Donovan			
	AH	6,143,306	11-7-2000	Donovan			
	AI	6,265,379 B1	7-24-2001	Donovan			
	AJ	6,299,893 B1	10-9-2001	Schwartz et al.			
	AK	6,306,403 B1	10-23-2001	Donovan			
	AL	6,306,423 B1	10-23-2001	Donovan et al.			
	AM	6,312,708 B1	11-6-2001	Donovan			
	AN	6,328,977 B1	12-11-2001	Donovan			
	AO	6,358,513 B1	3-19-2002	Voet et al.			
	AP	6,365,164 B1	4-2-2002	Schmidt			
	AQ	6,395,277 B1	5-28-2002	Graham			
	AR	6,423,319 B1	7-23-2002	Brooks et al.			
	AS	6,458,365 B1	10-1-2002	Aoki et al.			
✓	AT	6,464,986 B1	10-15-2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n )
BA						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Bigalke, Hans et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> ; <i>Brain Res</i> ; 1985; 360: pp 381-24
CB	Bigalke, H. et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord</i> ; <i>Naunyn Schmiedebergs Arch Pharmacol</i> ; 1981; 316; pp 244-51

EXAMINER W. J. [Signature] DATE CONSIDERED 3/2/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17595 (BOT)	SERIAL NO.: 10/621,054
APPLICANT CAERS, J. et al.	TITLE: DEVICE TO ASSIST HYPERHYDROSIS THERAPY
FILING DATE: July 15, 2003	GROUP 1645

CC	Binz, Thomas et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> ; <u>J Biochem</u> ; (Tokyo) 1990 Jun 5; 265(16); pp 9153-8
CD	Boyd, R.S. et al., <i>The insulin secreting B-cell line, HIT-15, contains SNAP-25 which is a target for botulinum neurotoxin-A</i> ; <u>Mov. Disorders</u> ; 1995; May; 10(3); 376
CE	Bushara, K.; <i>Botulinum toxin and rhinorrhea</i> ; <u>Otolaryngol Head Neck Surg</u> , 1996; 114(3); 507
CF	Ferrari, David M. et al., <i>The protein disulphide-isomerase family: unravelling a string of folds</i> ; <u>Biochem J</u> ; 1999 (339) pp 1-10
CG	Grimalt, R. et al.; <i>Multi-injection plate for Botulinum toxin application in the treatment of axillary hyperhidrosis</i> ; <u>Dermatol Surg</u> ; 2001, Jun; 27(6); 543-544
CH	Habermann; E.; <i>I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; <u>Naunyn-Schmiedeberg's Arch Pharmacol</u> ; 1974; 281; 47-56
CI	Habermann, E., <i>Inhibition by tetanus and botulinum A toxin of the release of [3H]noradrenaline and [3H]GABA from rat brain homogenate</i> ; <u>Experientia</u> ; 1988, Mar 15; 44(3) pp 224-6
CJ	Habermann, E. et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain</i> ; <u>J Neurochem</u> ; Vol 51, No 2 1988; pp 522-7
CK	Jankovic, Joseph et al., <i>Therapy with Botulinum Toxin</i> ; Marcel Dekker, Inc.; pp 5
CL	Marjama-Lyons, Jill et al., <i>Tremor-Predominant Parkinson's Disease</i> ; <u>Drugs &amp; Aging</u> ; 2000; April 16 (4) pp273-278
CM	Moyer, E. et al.; <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , pp 71-85 (chapter 6) of <u>Therapy With Botulinum Toxin</u> , edited by Jankovic, J. et al.; Marcel Dekker, Inc. 1994
CN	Naumann, Markus et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> ; <u>European Journal of Neurology</u> ; 1999, Vol 6 (suppl 4) pp S111-5
CO	Naumann, M.; <i>Botulinum toxin type A in the treatment of focal hyperhidrosis</i> ; <u>J. Cutaneous Laser Therapy</u> , 2001; 3(1); 42-43
CP	Pearce, Bruce et al., <i>Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine</i> ; <u>Toxicon</u> ; 1997; 35 (9); pp 1373-412 at 1393
CQ	Sanchez-Prieto, Jose et al., <i>Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes</i> ; <u>Eur J Biochem</u> ; 1987 Jun; 165 (3); pp 675-81

EXAMINER [Signature]

DATE CONSIDERED 3/2/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DEC 11 2003  
OIPF  
PATENT & TRADEMARK OFFICE

CR	Schantz, Edward J. et al., <i>Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine</i> ; <u>Microbiol Review</u> ; 1992 Mar; 56 (1); pp 80-99
CS	Singh; <i>Critical Aspects of Bacterial Protein Toxins</i> ; pp63-84 (chapter 4) of <u>Natural Toxins II</u> , edited by B.R. Singh et al., Plenum Press, New York 1976
CT	Sloop, Richard R. et al., <i>Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use</i> ; <u>Neurology</u> ; 1997, Jan; 48 (1); pp 249-53
CU	Weigand et al.; <i>I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection</i> ; <u>Nauny-Schmiedeberg's Arch Pharmacol</u> ; 1976, 292; 161-165

**EXAMINER** 

DATE CONSIDERED

372/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.